STAT44%
U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug 84%
By Ed Silverman62%
7/2/2026, 5:54:40 AM
BS Summary: This article contains 5 faulty reasoning types, including Framing Effect, Negativity Bias, and Quote-first Misdirection, with Biased Writer Voice as the most egregious example at 78.6% saturation with 114 hits. Analysis detected 314 faulty-reasoning hits from 145 analyzed words, generating a BS Score of 75.7% and a BS Rank of 84% (3,558 of 21,887 articles). This article is worse (more manipulative) than 83.70% of the article peer group.
In a victory for the pharmaceutical industry, a federal judge blocked a Colorado state panel from placing a cap on the price of a blockbuster drug sold by Amgen after deciding the company is “likely to be significantly harmed.”
The ruling pauses a controversial, first-in-the-nation move by the Colorado Prescription Drug Affordability Board, which was created four years ago in response to the rising cost of prescription medicines and is permitted to set upper payment limits on what most state residents will pay for selected drugs.
Several other states have similarly established affordability boards, although they all have somewhat different rules and criteria guiding their actions.
Colorado, however, has been moving more quickly than other states in choosing medicines that are deemed to be unaffordable and proceeding with decisions to create upper payment limits.
Speakers
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.